Épisodes

  • Parkinson’s Evidence Audit: LRRK2–SNCA–PARK7
    Feb 17 2026

    Parkinson’s Evidence Audit: LRRK2–SNCA–PARK7
    Research use only. Not medical advice. No drug recommendations.

    GaiaLab note:
    GaiaLab is evolving. I’m publishing public evidence audits first—then rolling improvements into the product once they’re robust and repeatable.

    Watch (YouTube): https://youtu.be/sgheeTQR94I
    Key PMIDs: 39153957, 35675433, 39487783, 39983584, 38368937, 33318422, 38391909, 34360787, 40140103, 39711195

    Afficher plus Afficher moins
    17 min
  • When Neutrophils Betray: 5 Precision Pivots Reshaping Colorectal Cancer
    Feb 10 2026

    Colorectal cancer isn’t a single bad gene you can “switch off.” It’s a living system—learning, rerouting, and evolving under pressure. In this episode, we follow the science where it gets uncomfortable: what if parts of our immune defense are quietly helping tumors escape?

    Inside the “precision pivot,” we unpack five surprising shifts redefining CRC treatment strategy:

    • The Neutrophil Betrayal: how ROS, proteases, and cytokines may “edit” oncogenic signaling via post-translational changes (still exploratory—but provocative).

    • The Precision Sweet Spot: why BRAF residues like F582/F655 could offer high impact with lower systemic toxicity potential.

    • Sorafenib’s Second Act: the repurposing gamble—targeting the BRAF/KRAS/NRAS axis and what the evidence does and doesn’t say.

    • The BRAF Paradox: why BRAF monotherapy can backfire in CRC—and why combo suppression is becoming the rule.

    • The “Moderate” Mutant: quieter BRAF variants that don’t roar… they hum—and still drive disease.

    This is not medical advice—just a deep, story-driven tour through the biology shaping the next era of CRC care.
    🎧 Follow GaiaLab: From Question to Insights for more science that thinks in systems, not slogans.

    🧪 Try GaiaLab: https://gaialab-production.up.railway.app/

    ▶️ YouTube: https://youtu.be/AD0GfWRKJOs


    Afficher plus Afficher moins
    16 min
  • Alzheimer’s Evidence Review in 92 Seconds: A GaiaLab Run (APP/PSEN1/APOE)
    Feb 3 2026

    In this episode, we demo GaiaLab on three Alzheimer’s-associated genes — APP, PSEN1, and APOE — to produce an evidence-first synthesis with confidence scoring, contradiction flags, and reproducible snapshots you can replay and audit.

    Run summary
    • 3 genes analyzed • 2 pathways found • 9 papers reviewed • 91,782 ms
    • Evidence quality: Strong consensus (84%) | Low contention (16%)
    • Quality score: 67/100 | Evidence Density: 28% | Contradiction Index: 16%
    • Citation coverage: 100% | Sources available: 15/16

    Top outputs
    • Pathway 1: Alzheimer disease — Homo sapiens (p=1.11e-3, medium confidence)
    • Pathway 2: Notch signaling — Homo sapiens (p=7.63e-3, medium confidence)
    • Strategy flagged: BACE1 inhibition to reduce Aβ production (low confidence, medium risk; evidence sparse)
    • Repurposing snapshot: 10 candidates flagged (avg score 45%); top candidate: Lecanemab (45% match; partial target match 33%; target APOE)

    Limitations noted by the run
    • Low evidence density → findings may be preliminary
    • DrugBank unavailable → drug evidence incomplete
    • DisGeNET disabled → disease association evidence incomplete

    Try GaiaLab: https://gaialab-production.up.railway.app/
    Replayable snapshots + evidence reports included.
    Research Use Only — Not medical advice.

    Afficher plus Afficher moins
    18 min
  • Hacking the Triple-Negative Resistance Network (TP53, BRCA1, EGFR) — GaiaLab
    Jan 27 2026

    In this episode, I use GaiaLab (evidence-first biological intelligence) to analyze TP53, BRCA1, and EGFR in triple-negative breast cancer (TNBC) — surfacing prioritized pathways, therapeutic strategies, and testable hypotheses.


    Highlights

    • Top pathway signal: EGFR tyrosine kinase inhibitor (TKI) resistance (p = 1.68e-4)

    • Therapy lanes: EGFR-targeted approaches + PARP inhibitors in BRCA-mutated TNBC

    • Hypotheses to validate: BRCA1–EGFR resistance axis, TP53–metabolism targeting, and a BRCA1+EGFR biomarker panel


    Trust & limits (important)

    • Consensus 52% vs Contention 48%

    • Evidence Density 34% (sparse)

    • Contradiction Index 100% (high) — treat this as hypothesis-generating

    • Research synthesis only — not medical advice


    Slides (PDF)

    https://drive.google.com/file/d/1095BEy5QBoy7B0qLEYZaSe5Qwb_mO7tY/view?usp=sharing


    Next episode:

    I’ll publish the YouTube video version and open submissions where you can send 2–5 genes + a disease context for analysis.


    Afficher plus Afficher moins
    14 min
  • From Question to Insights (GaiaLab) — Evidence-First Biological Intelligence
    Jan 24 2026

    GaiaLab is an evidence-first biological intelligence engine that turns a research question (or gene list) into traceable, cross-validated insights—fast.


    In this episode: From Question → Insights

    • How GaiaLab frames a biological question

    • Evidence pulled from curated sources

    • Cross-validation across independent datasets

    • Traceable claims + contradictions flagged

    • Outputs you can replay and reuse

    Watch the video on YouTube: https://www.youtube.com/watch?v=7A0XY-Gf7So
    Try GaiaLab: https://gaialab-production.up.railway.app/

    Notes:

    This content is for research/educational purposes and is not medical advice.


    Afficher plus Afficher moins
    16 min